SIRT1 and cancer: ASCs with TRAF3IP2 knockdown (ASCTRAF3IP2KD) did not exhibit changes in TRAF3IP2, NAMPT or SIRT1 levels, indicating a cancer-specific effect of TRAF3IP2 silencing (Fig. 2B).